Influenza vaccine commercialisation
As an addition to an already globally recognised World Vaccine Congress series, World Influenza Congress Europe is positioned as Europe's largest and most influential Influenza vaccine COMMERCIALISATION event.
- Hear what regional regulators expect in fast track product approval and licensure and how to quickly advance contracts
- Hear where industry still need to respond and which candidates can still generate commercial value from ongoing programmes
- Hear how you can position your organisation and its pipeline to commercialise existing Phase I, II and III candidates
- Hear what the future holds post H1N1 for previous H5N1 portfolios, seasonal requirements and an elusive universal vaccine
» contact us to find out more
» download the programme
meet new partners
1-2-1 partnering
Opportunities with "Contact" - Schedule dedicated onsite meetings with partners and gain the visibility your company needs.
»
networking opportunities
“I have attended a number of the WVC conferences over the years and they get better and better with higher calibre speakers and very timely and relevant subject areas”
Bill Enright, President and Chief Executive Officer, Vaxin
Biotech discounts
To ensure a balance of participant at the Congress we have organised some fantastic discounts for small / early stage biotechs. These exclusive prices can only be secured by contacting the Congress Director Neil Darkes directly.
»
get discount details
designed for networking
Key reasons to attend
- The World’s largest influenza and antivirals vaccine congress addressing global pandemic trends and key regulatory and industry response to the global H1N1
Major pandemic influenza A(H1N1) vaccine clinical progress and uptake including ongoing H5N1 pandemic and universal vaccine research, production and manufacture and antiviral application
- Over 45 sessions covering strategic pandemic influenza preparedness and response with unique industry showcases outlining critical progress in
Regulatory response, industry preparation, H1N1 and H5N1 R&D, antiviral combinations, influenza production, vaccine immunogenicity, novel DNA technology and novel antigen delivery vehicles
- Unrivalled global participation from regulators, pharma and biotech with every key player in the influenza market participating
Critical response from Baxter, Crucell, F. Hoffmann-La Roche, GSK Biologicals, Intercell, Novartis Vaccines & Diagnostics, sanofi pasteur, Solvay Biologicals and many more
